Boston Therapeutics Inc (BTHE) financial statements (2021 and earlier)

Company profile

Business Address 354 MERRIMACK STREET
LAWRENCE, MA 01843
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments118575279118
Cash and cash equivalents118575279118
Receivables    01 
Inventory, net of allowances, customer advances and progress billings3344678
Inventory3344678
Other undisclosed current assets2224413324363436
Total current assets:143846023339381452
Noncurrent Assets
Property, plant and equipment   1112
Intangible assets, net (including goodwill)    402439477
Intangible assets, net (excluding goodwill)    402439477
Total noncurrent assets:   1403440478
TOTAL ASSETS:143846024743821930
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,6791,9271,3911,0982,2862,0501,873
Accounts payable498450451458592595551
Accrued liabilities1,1811,1799412,4591,6941,4541,322
Employee-related liabilities 189     
Interest and dividends payable 110     
Other undisclosed accounts payable and accrued liabilities   (1,819)   
Debt200200650700700700700
Derivative instruments and hedges, liabilities36692848
Due to related parties3,0412,8112,5012,1011,5991,197808
Other undisclosed current liabilities3,4443,1763,3113,7881,7741,5071,500
Total current liabilities:8,3678,1207,8597,6966,3625,4614,929
Noncurrent Liabilities
Other undisclosed noncurrent liabilities     6891,062
Total noncurrent liabilities:     6891,062
Total liabilities:8,3678,1207,8597,6966,3626,1515,992
Stockholders' equity
Stockholders' equity attributable to parent, including:(8,224)(8,036)(7,799)(7,672)(5,619)(5,329)(5,061)
Preferred stock00     
Common stock111111111111111111111
Additional paid in capital19,32319,32319,32319,32319,21919,20519,192
Accumulated deficit(27,659)(27,470)(27,233)(27,106)(24,949)(24,646)(24,364)
Other undisclosed stockholders' equity attributable to parent  00000
Total stockholders' equity:(8,224)(8,036)(7,799)(7,672)(5,619)(5,329)(5,061)
TOTAL LIABILITIES AND EQUITY:143846024743821930

Income statement (P&L) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Gross profit:2333454
Operating expenses(212)(172)(137)(1,869)(652)(616)(740)
Operating loss:(210)(169)(134)(1,865)(648)(611)(736)
Interest and debt expense(111)(106)(98)(91)(82)(84)(86)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes   (201)427413(130)
Loss before gain (loss) on sale of properties:(321)(274)(232)(2,157)(303)(282)(952)
Other undisclosed net income  106    
Net loss:(321)(274)(126)(2,157)(303)(282)(952)
Other undisclosed net income attributable to parent13237     
Net loss available to common stockholders, diluted:(189)(237)(126)(2,157)(303)(282)(952)

Comprehensive Income ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Net loss:(321)(274)(126)(2,157)(303)(282)(952)
Comprehensive loss, net of tax, attributable to parent:(321)(274)(126)(2,157)(303)(282)(952)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: